Read the ASN Publications collection of articles highlights rapidly evolving research and treatment for kidney-heart disorders, including cardiovascular-kidney-metabolic syndrome. kidney.pub/kidneyhea...

🩳New short from Dr. Sumaiya Ahmed and @hswapnil.medsky.social #NephSky 🔮Can we use prediction models to determine who might benefit from steroids in IgAN before immunosuppression initiation? www.nephjc.com/news/2026/7/1/can-we-predict-who-benefits-from-steroids-in-igan-the-pred-igan-study

And @nejm.org retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!) www.nejm.org/doi/10.1056/... h/t @drjmluther.bsky.social #Avacopan #vasculitis

1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky

El resumen visual: MAJESTRY trial 👑 @dramiliflores.bsky.social and Dr. Divya Bajpai www.nephjc.com/news/ensayomajesty #NephSky #NephJC

The MAJESTRY trial, OBI vs TAC in membranous nephropathy. 👑 Visual abstract by Dr. Divya Bajpai #NephSky #NephJC www.nephjc.com/news/majestytrial

#NephMadness winner under attack🦎 Now it is just #madness #NephJC #NephSky

Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi

🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr

PREVENT-CVD better predicts combined cardio-kidney outcomes in CKD than traditional risk scores, according to #ASNCJASN study. Adding albuminuria boosts performance, highlighting its value for integrated cardio-renal risk assessment. https://twp.ai/9OW0ka

I don't think the public will grasp for some time how shocking these results are. I can foresee a future where many patients will just take retatrutide, because it literally fixes all the problems obesity causes. Diabetes too, it changes the equation immediately. Please share this far and wide!

#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...

First time at #ERA26 and I’ve already found the best idea…kidney art by school children #NephSky Check out more here: forms.office.com/Pages/Respon...

Visual abstract on uncovering non-diabetic-kidney disease in the diabetic patient by @dramiliflores.bsky.social #NephJ #NephSky #MedSky www.nephjc.com/news/2026/6/1/ndkd-the-visual-abstract

Esta vez, @dramiliflores.bsky.social estaba muy ocupada! VA en espanol #NephJC #NephSky #MedSky www.nephjc.com/news/2026/6/1/p9klc2s43l9rrgqifsxgenky9kj81t

Do you biopsy pts with diabetes? Are you looking for diabetic nephropathy or something else? Check out the blog by @dramiliflores.bsky.social and Dr. Priya John #NephSky #MedSky 📣Now with a "audio abstract" at the top, preview if you want to read more! www.nephjc.com/news/2026/6/1/kidneybiopsy-dkd

✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...

For 137 years, the Eiffel Tower honored 72 male scientists in gold lettering. Not one woman was included. Now Paris is adding the names of 72 women scientists to finally correct that history. Brilliant minds were always there. History just failed to recognize them. #SheShed

Rainy day watercolors

The underlying theme is that there is no “best” dialysis catheter. We think there is a ton of room for innovation in dialysis catheter design. The goal: a catheter that has the safety and longevity of an AVF. #NephSky @asdinnews.bsky.social journals.sagepub.com/doi/10.1177/...

1/ Hey #NephSky #MedSky 👋👋 Could a very high eGFR be a warning sign, not reassurance? This #KIreports editorial reframes "supra-normal" filtration as early cardiorenal stress and makes the case for a next-generation heat map www.kireports.org/article/S246...

#NephJC #TenPostNephJC. #NephSky 1/10 Building on the landmark findings of the SBP Intervention Trial, this study shows that team-based HTN care can successfully translate intensive BP control into meaningful CV benefits for underserved, low-income communities. pubmed.ncbi.nlm.nih.gov/41950472/

#NephSky #MedSky SPRINT told us that lower BPs improve CV outcomes. Can we implementation better BP strategies in low-income communities to achieve these goals? Guidelines are great, but real-world sustainable plans are better. #IMPACTSBP www.nephjc.com/news/2026-impact-bp

Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve BP control and adherence in low‑income patients 🎨 #VisualAbstract by @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/5/...

Happy #Caturday

In this edition, @nephroseeker.medsky.social breaks down the Bayesian voodoo behind removing evil humor www.nephjc.com/news/2026/sh... #EMIMCC #NephSky

Polymoxin hemoadsorption for sepsis? TIGRIS- a paper tiger 🐯 #NephSky #NephJC www.nephjc.com/news/2026/sh...

I have been WAITING for this exploratory analysis of renal outcomes from SURPASS CVOT! Long story short, no matter how you dice it tirzepatide significantly helps, even more so in severe CKD. #NephSky @mikejohansenmd.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social

Welcome to Friday At #NKFClinicals

Study in #JASN investigates: How do systemic glucocorticoids, opioids, and loop diuretics influence the diagnostic performance of cystatin C-based eGFR equations compared to gold-standard iohexol clearance (mGFR)? kidney.pub/JASN1108 Antoine Créon

Unearthed reports reveal that RFK Jr. fired every full-time CDC cruise ship sanitation inspector ahead of the Hantavirus cruise ship outbreak. www.cbsnews.com/news/cdc-cru...

🚨Another #NephJC short 🩳 FINE ONE: Finerenone in Type 1 Diabetes Fine, but does it cross the finish line? Blog by @nephromommy-akshu.bsky.social #NephSky #MedSky www.nephjc.com/news/2026/5/4/fineone

1/10 #NephJC #TenPost #NephSky In 2026 the only FDA approved 💊 for FSGS is sparsentan, an endothelin A/angiotensin II receptor inhibitor. Next up in the pipeline…transient receptor potential cation channel 6 (TRPC6) inhibitor (BI 764198) 🚰 Read the article 👇 www.pubmed.ncbi.nlm.nih.gov/41616795/

Do you struggle with FSGS? Are you a sparsentan fan but asking, what's next? TRPC6 inhibitors completed a phase 2 study! Are we closing in on a common pathway of FSGS pathology? Blog by @drsaivani.bsky.social & @sayalibthakare.bsky.social #NephSky #MedSky www.nephjc.com/news/trcpc6inhibition-fsgs

Meet the ASDIN Dream Team ✨ Incoming President Adrian Sequeira has introduced a refreshed committee structure for the 2026–2028 term, bringing together 21 committees and 122 dedicated members ready to make an impact. 👏 Check out the full lineup 👇 www.asdin.org/page/Committ...

👂So, did you hear the one about avacopan and data manipulation? 🧮🧮🧮 @hswapnil.medsky.social has added onto our ADVOCATE summary with a "postscript" review of the controversies. #NephSky #MedSky www.nephjc.com/news/advocate?rq=avacopan

💊FSGS precision medications started with AMKD (APOL-1) and inaxaplin. 💊This week we're discussing FSGS and what else is in the pipeline of therapeutics...TRPC6 inhibitors. #NephSky #MedSky Check out the VA by Dr. Divya Bajpai www.nephjc.com/news/2026/5/3/trpc6-inhibition-the-visual-abstract

Gracias @dramiliflores.bsky.social, el resumen visual en espanol #NephSky #MedSky www.nephjc.com/news/2026/trpc6-spanish

🚨A new KI Reports Community blog about Obinutuzumab. Wonderful review of how it differs from other anti-CD20 treatments, worth a read 📖 By Dr. Priyadarshini John #NephSky #MedSky www.kireportscommunity.org/post/beyond-...

A @kireports.bsky.social Community blog by @priti899.bsky.social on sexual health and CKD #NephTwitter #MedTwitter Are you asking all the right questions? 🚺 www.kireportscommunity.org/post/the-una...

Highlights from the upcoming first issue of KICR! www.theisn.org/blog/2026/04... @arvindcanchi.bsky.social @theisn.org

Which is a better treatment for people with hyperkalemia: sodium zirconium cyclosilicate (SZC) or patiromer? That depends. Find out why in the #ASNKidney360 study. kidney.pub/KID1173#ASNKidney360

How does the #axolotl achieve de novo nephron #regeneration following a partial nephrectomy? #BasicResearch in #ASNJASN kidney.pub/JASN1066

#NephJC #NephSky Cardiology 🫀 vs Nephrology 🫘 “Why’d you prescribe hydralazine for hypertension?”

Still ordering hydralazine? 🤔 Beyond case reports, this large cohort compares hydralazine vs ACEi/ARB to estimate real-world vasculitis risk, will this 📉 bias & clarify the answer Read more 👇 pubmed.ncbi.nlm.nih.... #TenPostNephJC #NephJC #NephSky #MedSky

Hydralazine is most classically associated with which serologic pattern in ANCA vasculitis? 25 min #TenPostNephJC #Nephsky #MedSky #NephJC A. High-titer PR3-ANCA B. High-titer MPO-ANCA C. ANCA− / anti-GBM+ D. anti-dsDNA antibodies

Do you prescribe hydralazine? Or, do you 🛑 it as soon as you see it? Hydralazine persists despite TID dosing & risks like... vasculitis 🔥 Are you asking Why-dralazine? ✅The blog by @dramiliflores.bsky.social @nephroseeker.medsky.social #NephSky www.nephjc.com/news/hydralazine-anca-vasculitis

Check out the VA on hydralazine and population vasculitis risk by Dr. Divya Bajpai #NephSky www.nephjc.com/news/2026/4/hydralazine-anca-va

#RPA26 Words of wisdom 🤔 from the ATL